focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,772.50
Bid: 1,772.00
Ask: 1,772.50
Change: -11.00 (-0.62%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks Trade Higher Despite Retail Sales Miss

Fri, 21st Feb 2014 10:47

LONDON (Alliance News) - The FTSE 100 is on track to post its sixth consecutive daily rise Friday, as weaker-than-expected UK retail sales and public finances data failed to dent the recent market positivity.

By mid-morning, the FTSE 100 is up 0.4% at 6,836.91, just over 30 points shy of its highest level in 2014, the FTSE 250 is up 0.3% at 16,415.65, and the AIM All-Share index is marginally higher at 882.99.

British retail sales declined more-than-expected in January. Including automotive fuel, retail sales fell 1.5% month-on-month, the first decline in three months, the Office for National Statistics said. Economists had been expecting a more modest 1% decrease, after the 2.5% rise in December.

At the same time, the Office of National Statistics published UK public finances data for January. The UK public sector net borrowing posted a surplus of GBP6.43 billion in January, having recorded a GBP9.03 billion deficit in December.

In the forex market, the pound has retaken the losses it made before the data was published. The currency was trading at a weekly low of USD1.661 at the time of the release, but is now at USD1.6668. Similarly, after dipping against the Swiss franc and the euro, sterling now trades at CHF1.4843 and EUR1.2161.

At the individual UK stock level, Royal Bank of Scotland, up 1.4%, is amongst the biggest risers in the FTSE 100. The group is preparing a dramatic retrenchment that would see it become a much smaller UK retail and commercial bank, a move that is expected to see staff numbers slashed by at least 30,000 in the coming years, the Financial Times reported Friday.

Shore Capital has reiterated its Buy recommendation, saying that the move is likely to result in a, "smaller but more efficient, higher return and less risky bank."

GlaxoSmithKline, up 1%, is another big riser. The drugs giant said that Incruse, a treatment for chronic obstructive pulmonary disease, had been recommended for marketing authorisation by the European Medicines Agency's committee for Medical Products for Human Use, a key step in getting approval for the drug.

The news comes after Anoro, another treatment for the disease, was also recommended for marketing authorisation by the committee on Thursday.

In the FTSE 250, Millennium & Copthorne Hotels and IP Group are the stand-out performers.

Millennium & Copthorne reported a pretax profit of GBP167.7 million for the fourth quarter of 2013, up from only GBP54.2 million a year earlier, and recorded a pretax profit of GBP263.6 million for the year as a whole, compared with a profit of GBP171.3 million in 2012.

IP Group, meanwhile, has jumped after it said its portfolio company, Xeros Ltd, intends to float on AIM to raise funds to bring its cleaning product to the laundry market.

Still to come in the data calendar Friday, US existing home sales data is released at 1500 GMT, before President of the Federal Reserve Bank of St. Louis James Bullard gives a speech at 1810 GMT.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.